New Delhi, Dec. 26 -- Ajanta Pharma Ltd announced an in-licensing agreement with Biocon this week to market semaglutide across 26 emerging markets, including Africa, West Asia, and Central Asia. The patent for the weight loss drug expires in most of these markets by March, with commercialisation expected post regulatory approvals in late 2026 or early 2027. While this will not immediately impact earnings, it can potentially influence Ajanta's medium-term growth.

To start with, Ajanta is not stepping into unfamiliar territory. The company already has a strong branded generics presence in over 30 countries, supported by over 2,000 medical representatives. This significantly reduces execution risk.

PL Capital expects semaglutide to provide...